No standardized guidelines exist for ANE1 maintenance therapy, but maintenance IVIG may modulate overactive immune responses and reduce infection-triggered ANE episodes, particularly in young children at high risk of severe and fatal disease. The gene discussed is RANBP2; the disease is infection.